Royalty Pharma plc [RPRX] stock prices are saw in change for the day to $39.16 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RPRX shares have gain 1.61% over the last week, with a monthly amount glided 5.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Royalty Pharma plc [NASDAQ: RPRX] stock has seen the most recent analyst activity on September 30, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $42. Previously, Morgan Stanley started tracking the stock with Overweight rating on May 16, 2025, and set its price target to $51. On June 03, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $28 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $53 as its price target on May 13, 2022. Goldman started tracking with a Buy rating for this stock on April 27, 2022, and assigned it a price target of $56. In a note dated April 14, 2022, JP Morgan upgraded an Overweight rating on this stock but restated the target price of $50.
The stock price of Royalty Pharma plc [RPRX] has been fluctuating between $24.05 and $41.24 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Royalty Pharma plc [NASDAQ: RPRX] shares were valued at $39.16 at the most recent close of the market. An investor can expect a potential return of 22.57% based on the average RPRX price forecast.
Analyzing the RPRX fundamentals
The Royalty Pharma plc [NASDAQ:RPRX] reported sales of 2.35B for trailing twelve months, representing a surge of 7.90%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.8%, Pretax Profit Margin comes in at 0.72%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.15 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 38.92 points at the first support level, and at 38.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.45, and for the 2nd resistance point, it is at 39.74.
Ratios To Look Out For
It’s worth pointing out that Royalty Pharma plc [NASDAQ:RPRX]’s Current Ratio is 3.48. In addition, the Quick Ratio stands at 3.48 and the Cash Ratio stands at 0.52. Considering the valuation of this stock, the price to sales ratio is 9.62, the price to book ratio is 2.62 and price to earnings (TTM) ratio is 22.39.
Transactions by insiders
Recent insider trading involved Terrance Coyne, Officer, that happened on Nov 17 ’25 when 69594.0 shares were purchased. Director, Norden Gregory completed a deal on Aug 11 ’25 to sell 33500.0 shares. Meanwhile, Director Norden Gregory bought 33500.0 shares on Aug 11 ’25.
